CompanyPMNNasdaqToronto, A6

ProMis Neurosciences, Inc

ProMIS Neurosciences develops therapeutic antibodies and vaccines targeting toxic oligomers in neurodegenerative diseases.

SEC EDGAR ClinicalTrials.gov promisneurosciences.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 13Latest story

August 2026

ProMIS reports interim PRECISE-AD data showing no ARIA-E, ends Q2 with $53.4 million

Aug 13Quarterly updatePMN310 ProMis Neurosciences, Inc